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Abstract: CONTEXT Primary aldosteronism (PA) is associated with higher cardiovascular morbidity
and metabolic risks. Recent studies report glucocorticoid co-secretion as a relevant phenotype of PA,
which could contribute to associated risks, including type 2 diabetes mellitus (T2DM). The relationship
between autonomous cortisol secretion (ACS) and glucose metabolism in PA has not been investigated.
OBJECTIVE To evaluate the prevalence of impaired glucose homeostasis in PA patients according to
cortisol co-secretion. METHODS We performed oral-glucose-tolerance-tests (OGTT) and complete test-
ing for hypercortisolism (1mg-dexamethasone-suppression-test (DST), late-night-salivary-cortisol (LNC),
24hour-urinary-free-cortisol (UFC)) in 161 newly diagnosed PA patients of the German Conn Registry.
76 of 161 patients were reevaluated at follow-up. We compared our results to a population-based sample
from the KORA-F4 study matched to the PA participants (3:1) by sex, age, and BMI. RESULTS At the
time of diagnosis, 125 patients (77.6%) had a pathological response in at least one of the Cushing screening
tests; T2DM was diagnosed in 6.4% of these 125 cases. Patients with pathological DST exhibited signifi-
cantly higher 2h plasma glucose in OGTT and were significantly more often diagnosed with T2DM than
patients with normal DST (20% vs. 0.8%, p<0.0001) and matched controls from the KORA study (20.6%
vs. 5.9%.; p=0.022). PA patients without ACS tended to have higher homeostatic-model-assessment-
of-insulin-resistance (HOMA-IR) than KORA control subjects (p=0.05). CONCLUSION ACS appears
frequently in PA patients and is associated with impaired glucose metabolism, which could increase the
risk of T2DM. PA itself seems to enhance insulin resistance.
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Context: Primary aldosteronism (PA) is associated with higher cardiovascular morbidity and 
metabolic risks. Recent studies report glucocorticoid -secretion as a relevant phenotype of 
PA, which could contribute to associated risks, including type 2 diabetes mellitus (T2DM). 
The relationship between autonomous cortisol secretion (ACS) and glucose metabolism in 
PA has not been investigated. 
Objective: To evaluate the prevalence of impaired glucose homeostasis in PA patients 
according to cortisol co-secretion. 
Methods: We performed oral-glucose-tolerance-tests (OGTT) and complete testing for 
hypercortisolism (1mg-dexamethasone-suppression-test (DST), late-night-salivary-cortisol 
(LNC), 24hour-urinary-free-cortisol (UFC)) in 161 newly diagnosed PA patients of the 
German Conn Registry. 76 of 161 patients were reevaluated at follow-up. We compared our 
results to a population-based sample from the KORA-F4 study matched to the PA 
participants (3:1) by sex, age, and BMI. 
Results: At the time of diagnosis, 125 patients (77.6%) had a pathological response in at least 
one of the Cushing screening tests; T2DM was diagnosed in 6.4% of these 125 cases. Patients 
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significantly more often diagnosed with T2DM than patients with normal DST (20% vs. 
0.8%, p<0.0001) and matched controls from the KORA study (20.6% vs. 5.9%.; p=0.022). 
PA patients without ACS tended to have higher homeostatic-model-assessment-of-insulin-
resistance (HOMA-IR) than KORA control subjects (p=0.05). 
Conclusion: ACS appears frequently in PA patients and is associated with impaired glucose 
metabolism, which could increase the risk of T2DM. PA itself seems to enhance insulin 
resistance. 
Analysis of 161 patients with primary hyperaldosteronism (PA) and comparison to matched controls 
revealed that autonomous cortisol secretion in PA is associated with impaired glucose homeostasis. 
Introduction 
Primary aldosteronism (PA) is the most common endocrine form of secondary hypertension 
that affects 4.3 to 9.0% of hypertensive patients 1. Patients with aldosterone excess are at a 
higher risk of cardiovascular events and metabolic comorbidities in comparison to patients 
with essential hypertension 2-4. Recent studies have proven a broader metabolic influence of 
PA than previously suggested including impaired insuli -secretion 5, insulin-sensitivity 6 and 
other effects of aldosterone on glucose metabolism 7. These mechanisms lead to a higher 
prevalence of the metabolic syndrome and type 2 diabetes mellitus (T2DM) in PA patients 8. 
However, some aspects of impairment of glucose homeostasis in PA are still unresolved. 
In the past, cortisol co-secretion in primary aldosteronism has been discussed on the basis 
of several case studies or case series 9-15. Recently, we have investigated a large multi-center 
cohort of PA patients and revealed that glucocorticid o-secretion is a phenotype frequently 
found in PA which might contribute to associated metabolic risks 16, including a higher risk 
of cardiovascular events as shown by Nakajima et al. 17. Specifically, our findings suggest 
that cortisol excess in PA also plays a role in impaired glucose metabolism. However, further 
investigations of the underlying mechanisms have not been undertaken yet. 
Therefore, we analyzed autonomous cortisol secretion (ACS) and glucose metabolism in 
detail in newly diagnosed PA patients of the German Co n Registry. In addition, we used the 
population-based Cooperative Health Research in the-region of Augsburg (KORA)-F4 study 
with a 3:1 matching by sex, age, and BMI for comparison. 
 Methods 
Study Population 
The German Conn Registry 
The study population consists of 161 patients that were recruited in two centers (Munich; 
Berlin) of the German Conn Registry. The German Conn Registry is a multicenter-registry 
that investigates therapy, comorbidities and the longtime-outcome in PA-patients throughout 
Germany since 2008 18. The investigated cohort was obtained between February 2013 and 
April 2017.  
For inclusion in the registry, patients had to meet th  diagnostic criteria for PA, as stated 
in the guidelines of the Endocrine Society 19. Patients were usually screened with high blood 
pressure and abnormal aldosterone to renin ratio (ARR) and then underwent one or more 
confirmatory tests (saline infusion, fludrocortisone suppression, captopril test, oral salt 
loading test with elevated excretion of aldosterone a d metabolites in urine). Before 
implementation of those tests (including standard oral glucose tolerance test (OGTT) and 
complete testing for hypercortisolism), anti-hypertensive medication was changed whenever 
possible or indicated (deduction of beta-blockers, central-alpha-agonists, angiotensin-
converting-enzyme-blocker, angiotensin-receptor-blocker for at least one week and 
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to prevent influences on renin-angiotensin-aldostern -system and thus test results. The 
diagnosis was then made decentralized in the synopsis f all clinical and laboratory findings 
according to the guidelines of the Endocrine Society.  
Subtype identification (aldosterone producing adenoma (APA) vs. bilateral adrenal 
hyperplasia (BAH)) was performed via adrenal imaging (MRI or CT) and adrenal vein 
sampling (AVS), which was realized in 95.7% (n=154) of patients and successful in 89.6% 
(n=138) of those. During AVS, blood is obtained from both adrenal veins and a peripheral 
vein. We assessed blood samples for hormone levels of both aldosterone and cortisol, in order 
to correct a dilution effect and confirm correct caheterization 19. Catheterization was 
performed without cosyntropin stimulation and was considered successful when cortisol 
levels in both adrenal veins were at least twice as high as in vena cava inferior. Unilateral 
aldosterone excess was considered to be present in pa ients with a lateralization index 
((aldosterone left/cortisol left)/(aldosterone right/cortisol right) or vice versa) of at least 4:1. 
For the present study, all PA patients underwent a standard OGTT and complete testing 
for hypercortisolism, including 1mg dexamethasone suppression test (DST), 24hour urinary 
free cortisol (UFC) and late-night salivary cortisol (LSC) at baseline visit. Patients with 
missing data for aldosterone, renin, potassium, OGTT or blood pressure were excluded. Also, 
PA patients with a previously known diabetes mellitus were excluded. We assessed glucose 
metabolism by laboratory measurement and OGTT, according to the American Diabetes 
Association 20. 76 of 161 patients had a follow-up visit one year after therapy initiation with 
MRA or adrenalectomy (ADX). The Ethics Committees of the Klinikum of the University of 
Munich and of the Conn´s registry participating centers approved the protocol. Personal data 
protection laws were strictly adhered to. All included patients gave their written informed 
consent. 
KORA-Study 
The KORA-F4 study is the 7-year-follow-up examination of the population-based KORA-S4 
study 21, 22. Baseline-examinations of KORA-S4 were conducted in 1999-2001 (n=4261) in 
men and women aged 25-74 years. In 1353 participants aged 55-74 years an OGTT was 
performed at baseline 23. 3080 participants were re-investigated in 2006-2008 as part of 
KORA-F4. These participants comprise the basis for the present analyses. Investigations 
included a standard medical interview, physical examin tion, blood withdrawal, and an 
OGTT in all individuals without known T2DM after an overnight fasting period of ≥8h 24, 25. 
The KORA studies were approved by the Ethics Committee of the Bavarian Medical 
Association. Written informed consent was obtained from all participants, and data protection 
policies strictly adhered to. 
Definitions and laboratory measurements 
In PA patients as well as in controls standard labor tory measurements were performed 
immediately and decentralized. Measurements of cortisol and ACTH were performed as 
previously described 26. Measurement of serum cortisol and plasma ACTH was performed 
with Solid Phase Antigen linked Technique (Cortisol, SPALT, Liaison, DiaSorin, Saluggia, 
Italy) and chemiluminescence immuno-assay (ACTH, CLIA, iaison, DiaSorin). Within- and 
between-assay coefficients of variation were below 5 and 7% (Cortisol) and below 13% 
(ACTH) respectively. Urinary cortisol measurement was performed with chemiluminescence 
immunoassay (ADVIA Centaur, Siemens) with within- ad between-assay coefficients 
variations below 7%. Salivary cortisol was measured by a luminescence immunoassay 
(Cortisol LIA, IBL, Hamburg, Germany) with within- and between-assay coefficients 
variations below 9% and 6%. 
In order to test for hypercortisolism, we performed 1mg DST and acquired LSC, as well 
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indicator for hypercortisolism was assumed when DST, LSC or UFC were above normal 
reference values (≥51 nmol/l; >1.45 ng/ml; >150 µg/24hours, respectively). Reference values 
were determined following the Guidelines of the Endocrine Society 27.  
Blood pressure (BP) was measured up to three times on each arm after at least 5 minutes 
of resting with standard sphygmomanometers. Body mass index (BMI) was calculated as 
body weight (kg) per heights2 (m2).  
The homeostasis model assessment of insulin resistance (HOMA-IR) score was 
calculated (fasting serum insulin (mU/l) * fasting plasma glucose (mg/dl) /405) for patients of 
the German’s Conn Registry and (fasting serum insuli  (mU⁄ l * fasting plasma glucose 
(mmol/l)) ⁄ 22.5) for KORA-F4 participants. HOMA-β, as estimate for β-cell function, was 
calculated using the following formula: 20 × fasting i sulin (µIU/ml) / (fasting plasma 
glucose (mmol/l) - 3.5). In order to investigate glucose metabolism, we performed an OGTT 
at baseline in all patients and measured HbA1c (%) in patient’s blood samples. Only non-
diabetic Conn patients and non-diabetic KORA participants (= no intake of antidiabetic 
drugs, no diagnosis by another physician, no reportd T2DM by the patient) received an 
OGTT.  
OGTT was performed after an overnight fast of at lest 8 hours with 75g glucose 
dissolved in 300ml of water. Blood samples were obtained before glucose load (fasting 
plasma glucose; FPG) and 120minutes (2h glucose) after glucose load. Patients were 
diagnosed with either T2DM, prediabetes or normal glucose metabolism, according to the 
American Diabetes Society 20: newly detected T2DM was defined if HbA1c ≥6.5%, FPG ≥ 
126 mg/dl or glucose at 120 minutes of OGTT ≥ 200mg/dl. Prediabetes was defined by 
HbA1c (5.7-6.4%) or OGTT result in either impaired FPG (100-125 mg/dl in OGTT) or 
impaired glucose tolerance (IGT 140-199 mg/dl in OGTT). The term prediabetes includes 
isolated impaired FPG, isolated IGT and both combined. All KORA participants with 
clinically diagnosed diabetes who did not receive an OGTT were included in the diabetes 
group in analyses regarding diabetes prevalence. 
Matching and Statistical analysis  
Matching was performed sex-stratified and further matching variables were age (+/- 5 years) 
and BMI-category (<25; 25-29; ≥30kg/m2). In order to be able to achieve a 3:1 matching, 
four young patients (<32 years) from the German-Conn-Registry had to be excluded. Blood-
pressure was not chosen as a matching variable, as KORA participants are population-based 
whereas PA patients form a hypertensive cohort. KORA participants with type 1 or type 2 
diabetes or drug induced diabetes were excluded, as well as participants with ARR >20 and 
those with missing values of systolic or diastolic blood pressure, fasting glucose or renin 
concentrations. This 3:1 matching resulted in 471 matched KORA participants (controls) for 
157 PA patients. Differences between PA patients and co trols were obtained using 
conditional regression analysis. 
Statistical analysis was carried out using IBM SPSS Statistics 25.0 (IBM, Ehningen, 
Germany). Data are displayed as mean and standard deviation (mean ± SD) for normally 
distributed continuous data, and as median; 25th and 75th percentile for continuous variables 
without normal distribution. Categorical variables are displayed as percentage or numbers. 
Variables were assessed for normal distribution usig Shapiro-Wilk test.  
To compare normal and pathological subgroups we used either Mann-Whitney U test or 
unpaired t-test for continuous data and Chi2 test for categorical variables. For paired data 
comparing baseline and follow-up visit, we used McNemar for categorical data and Wilcoxon 
signed rank test or paired t-test for continuous data. T-Tests (paired or unpaired) was only 
applied if normal distribution in both subgroups was given. Differences were considered 















































































































































































In 161 investigated PA patients, ACS was identified in 77.6% (n=125; 61 with one, 58 with 
two, and 6 with three pathological tests), whereas 22.4% (n=36) showed a normal response in 
all three tests for hypercortisolism (noACS). We found no differences in age, BMI, BP, 
potassium or lipid parameters between the groups (Table 1). However, women with ACS had 
a significantly higher WHR than women without ACS (Table 1). PA patients with ACS had 
significantly higher ARR in comparison to the noACS subgroup (79.2; 43.6-141 vs. 60.0; 
30.6-94.9; p=0.029), and showed a higher lateralization rate (49.6% vs. 30.6%; p=0.043). 
T2DM was diagnosed in 6.4% of the PA patients with ACS, while no T2DM was apparent in 
any patients of the noACS subgroup (p=0.119) (Figure 1). The prevalence of prediabetes 
(27.8% vs 27.2%; p=0.945) and of the metabolic syndrome (19.4% vs. 16.0%; p=0.626) was 
not different between the noACS and the ACS subgroup (Figure 1). Also, no differences 
were detected regarding FPG, 2h plasma glucose levels or HOMA-IR.  
In PA patients with ACS we found significant differences in ARR (156±156 vs 112±185; 
p=0.006) and potassium (3.5±0.4 vs 3.7±0.3 mmol/l; p=0.033) levels between patients with 
unilateral and bilateral disease, however no differences were seen in parameters of glucose 
homeostasis. In PA patients with noACS, potassium (3.3±0.4 vs 3.7±0.3 mmol/l; p=0.005) 
significantly differed between patients with unilateral and bilateral disease, however also no 
differences were seen in parameters of glucose homeostasis. 
We further analyzed ACS depending on the DST results only: 35 of 161 patients (21.7%) 
were found to have a pathological response in DST (pathDST). PA patients with pathDST 
displayed a tendency towards a higher 2h plasma glucose levels (p=0.053) in OGTT than PA 
patients with normalDST (Figure 2). This resulted in a significantly higher prevalenc  for 
T2DM in the pathDST-subgroup (20% vs. 0.8%, p<0.0001). However, FPG, HbA1c, 
HOMA-IR and the prediabetes prevalence were not different between pathDST and 
normalDST subgroups. Also, no differences were seen in other clinical and lab parameters.  
To further explore these findings, we matched 158 patients of our cohort 1:3 with 
participants of the KORA-F4 study. We further aimed to differentiate between effects of 
aldosterone excess and ACS on glucose homeostasis by using the KORA study. In a first 
step, we compared the characteristics of PA patients without ACS (n=35) to matched KORA 
controls (n=105) (Table 2). PA patients without ACS showed no difference in fasting plasma 
glucose or 2h plasma glucose levels in OGTT compared to matched controls. However, 
HOMA-IR was higher with a borderline significance (p=0.051) than in matched controls 
(Table 2) suggesting insulin resistance due to hyperaldoster nism. PA patients without ACS 
showed no difference in HbA1c, but a significantly higher WHR than matched controls 
(Table 2). Furthermore, LDL cholesterol (115±29.9 vs. 135±39.4; p=0.010) and total 
cholesterol levels (194±33.5 vs. 217.5±40.5; p=0.004) were significantly lower in PA 
patients without ACS than controls. 
The next step was to compare PA patients with ACS, proven by pathological DST 
(pathDST), (n=34) with matched controls from the KORA study (n=102) (Table 3). PA 
patients with ACS showed no difference in fasting plasma glucose or HOMA-IR compared to 
matched controls. However, the 2h plasma glucose levels in OGTT were significantly higher 
(p=0.001) than in matched controls (Table 3) indicating impaired glucose tolerance. This 
subgroup of PA patients with ACS also presented with significantly lower HbA1c and higher 
WHR (Table 3), as well as lower triglycerides (78.5; 57.5-127 vs. 98.5; 64.0-253; p=0.041) 
and cholesterol levels (201±34.6 vs. 218±41.6; p=0.041) than matched controls.  
We also compared 63 PA patients with a pathLSC to matched KORA individuals 
(n=189). Thereby, we detected lower fasting plasma glucose levels in PA patients with 
pathLSC compared to matched controls, while no difference in HOMA-IR was evident. 
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significantly higher (p=0.002) in PA patients with pathLSC than in matched contrls, 
whereas they presented with significantly lower HbA1c and higher WHR. The same pattern 
(significantly (p=0.0004) higher 2h plasma glucose levels in OGTT) was found in 93 PA 
patients with pathUFC compared to their matched KORA controls (n=279). 
We further evaluated additive effects when considering multiple pathological tests. Two 
pathological test results for hypercortisolism showed greater significance regarding 
differences in 2h plasma glucose in OGTT (p=0.001) compared to matched KORA subjects. 
Due to a small number of patients with three pathological test results for hypercortisolism 
(n=6), statistical analysis was not performed. 
76 of 161 patients received follow-up visit one year after initiation of therapy (32.9% 
ADX; 63.2% MRA; 3.9% other therapies) and characteris ics are showed in Table 4. At 
follow-up we documented post-operative adrenal insufficiency in 5 of the 25 ADX patients 
with no difference in prevalence between ACS and noACS patients. Those 5 patients 
temporarily received hydrocortisone treatment; and no adrenal crisis occurred. At follow-up, 
patients showed a significant (p<0.001) decrease in BP, an increase in potassium and 
decrease in ARR. BMI and WHR did not change; however, HbA1c levels were significantly 
higher at follow-up. 23.7% of the follow-up patients were in the noACS-subgroup (n=18), 
and 76.3% in the ACS-subgroup (n=58).  
In PA patients without ACS no significant changes in prevalence of prediabetes or T2DM 
were seen between baseline and follow-up (Figure 3a). Also, in PA patients with ACS, no 
significant changes in prevalence of prediabetes or T2DM were observed (Figure 3b), even 
when some patients improved from the T2DM to the prediabetes and from the prediabetes 
group to the normal-glucose-homeostasis group, other patients worsened on follow-up to the 
prediabetes or T2DM group. 
Discussion 
Patients with PA are characterized by a significantly i creased risk to develop further 
comorbidities, including cardiovascular, renal and cerebrovascular disease. These risks are 
usually significantly higher than in hypertensive patients and thus are attributed to 
aldosterone excess 2-4.  
Among others, APA induced hypokalemia is stated as a secondary cause for T2DM by 
the American Diabetes Association 20. Diabetes prevalence in PA ranges from 8.2% to 23%, 
depending on the study population and the applied diagnostic criteria 8, 28-31. Even though 
some studies could not show an increased risk of T2DM in PA patients 29, 31 other studies are 
in favor of this assumption. For example, a retrospective cohort of the German Conn’s 
registry established a significantly increased riskfor T2DM (23% vs. 13%, P=0.03) in 
comparison to hypertensive control subjects 30. These results were confirmed by a 
prospective study of Hanslik et al. who could demonstrate a prevalence of 17.2% for T2DM 
in PA patients, which was significantly higher than in their population-based control cohort 8.  
Different mechanisms that lead to glucose impairment in PA have been discussed 32. One 
major contributing factor for PA patients to develop T2DM seems to be hypokalemia, which 
impairs insulin release by pancreatic beta-cells 33. Other mechanism that lead to impaired 
glucose tolerance in PA include reduced insulin sensitivity and impaired insulin signaling and 
thus reduced glucose uptake in peripheral tissue, including liver, skeletal muscle and adipose 
tissue 34-36. Furthermore, aldosterone induces reactive oxygen spcies (ROS) and increases 
insulin-like growth-factor-1 expression, ultimately causing endothelial dysfunction which 
leads to an impaired glucose diffusion 37, 38. Finally, adipose tissue expresses both 
mineralocorticoid receptor (MR) and glucocorticoid receptor (GR). Due to absence of 11β-
hydroxysteroid dehydrogenase (11β-HSD) type 2 in adipocytes, the MR is thought to be at 
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cortisone by 11β-HSD type 1 39. Therefore, we hypothesize that cortisol cosecretion in PA 
might alter adipocyte differentiation and subsequently i fluence insulin sensitivity and 
glucose homeostasis. 
One further aspect of PA that might result in disturbances of glucose metabolism is 
glucocorticoid co-secretion. First, a possible cortis l co-secretion in PA patients could only 
be shown in a few patients of small sized retrospectiv  ohorts 10, 17. However, recently larger 
studies suggest that glucocorticoid excess (autonomus cortisol secretion, ACS) is a frequent 
finding in PA 16, 40. We demonstrated a correlation of 24-hour glucocortic id output with 
markers of insulin resistance - including fasting isulin, insulin after OGTT and HOMA-IR. 
Thus, indicating that glucocorticoid co-secretion might affect glucose homeostasis.  
However, we now present the first study to evaluate the impact of ACS on the prevalence 
of T2DM in PA in comparison to a 1:3 matched control gr up. We prospectively investigated 
ACS with the help of three different tests for hypercortisolism and set them into context with 
results of OGTT. We could identify 125 patients (77.6%) with ACS in at least one of the tests 
and 34 patients (21.1%) with pathological response i  DST alone. Until now smaller studies 
estimated the prevalence of cortisol excess in PA patients at 3.9%-33.3%, depending on the 
diagnostic criteria used 9-11, 17. Most of the studies used DST as their main diagnostic criteria 
in combination with another feature of ACS, formerly named subclinical hypercortisolism. 
On this basis, we prove that ACS is a frequent finding in PA and should be considered as 
another factor of comorbidities in PA patients. It is important to point out that mild 
autonomous cortisol secretion (MACE) contributes to lower bone mineral density, and might 
have the same effect in our PA patients with ACS41. 
In our cohort, we could show that PA patients with ACS have a higher prevalence of 
T2DM than sex, age, and BMI-matched controls. In cotrast to this, PA patients without ASC 
– and thus with aldosterone excess alone - could not be diagnosed with T2DM, but showed 
higher HOMA-IR values than their matched KORA-contrls. HOMA-IR is known as a 
marker of hepatic glucose and insulin in the fasting state 42. This leads to the assumption that 
aldosterone might directly affect hepatic insulin-resistance. Previous studies have shown that 
aldosterone administration increases FPG and leads to an increased expression of 
gluconeogenetic enzymes 43, which might lead to the observed deterioration of HOMA-IR 
values.  
Investigating the effect of ACS in PA on glucose home stasis, we detected that PA 
patients with proven ACS showed higher 2h glucose lev ls during the OGTT and a higher 
prevalence of T2DM compared to matched KORA-controls. Thus, it seems that an additional 
ACS impairs glucose tolerance in the peripheral tissue . Possible mechanisms might include 
impairment of insulin-dependent glucose uptake in peripheral tissue 44 or enhanced 
gluconeogenesis via different mechanisms, including further induction of gluconeogenetic 
enzymes 45. Furthermore, the presence of more than one abnormal test depicting cortisol 
excess seems to be associated with a greater risk of impaired glucose tolerance. 
Interestingly, parameters of glycemia of our patients did not improve at follow-up after 12 
months. This is in contrast to the study by Catena et al.46 which showed improved glucose 
homeostasis after 6 months of treatment. However, this s udy included only 47 PA patients, 
and glucose homeostasis worsened again over a longer follow-up 46. In our patients treated 
with ADX the source of aldosterone and glucocorticoid excess seems to be removed and thus 
usually these patients perform better in follow-up studies than patients treated with MRA. 
Still, some patients treated with ADX do not show complete biochemical cure. The reasons 
for this were summarized recently and comprise surgery based on CT subtyping, different 
accuracy of simultaneous and sequential AVS or usage of different selectivity and 
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age, unhealthy diet, physical inactivity or stress, or the small number of patients with follow-
up data.  
One limitation of the present study is that only 12 patients without T2DM at baseline 
agreed to redo an OGTT and ACS was not reevaluated at follow-up so that effects of 
glucocorticoids on glucose metabolism over time might be distorted. In addition, LSC, DST 
and UFC were not repeated after treatment, and, thus we cannot rule out that mild cortisol 
excess persisted in some patients. Furthermore, we did not investigate other factors that might 
influence the development of glucose intolerance, such as family history of diabetes or drug-
induced diabetes. The strengths of our study are that the German Conn Registry, as well as 
the KORA-F4 study, collects data in a prospective and standardized manner. We can present 
a large-sized and well-characterized cohort with follow-up investigations. We could match 
our PA patients in a 1:3 sex, age, and BMI-based matching to participants from a population-
based study, in order to achieve a case-control-design. A further limitation of our study might 
be that in PA patients with ACS the cortisol hypersec etion might interfere with the 
interpretation of the AVS data because up to now cortisol, and not plasma metanephrine48, is 
used as normalization factor in AVS aldosterone measurements. 
In conclusion, we show that our PA cohort possesses a high proportion of patients with 
ACS. We describe that T2DM and impaired 2h plasma glucose in OGTT is more prevalent in 
PA patients with ACS than in controls matched for sex, age, and BMI. These results give 
further evidence for the “Connshing” syndrome and point out the relevance for further 
investigation of the underlying mechanisms and especially associated risks such as T2DM. 
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Figure 1: Frequencies in glucose metabolism alterations of patients with primary 
aldosteronism at baseline visit and complete testing for hypercortisolism (n=161). No 
autonomous cortisol secretion (ACS) – patients with normal test results regarding 
hypercortisolism; ACS – patients with pathological response in at least one test for 
hypercortisolism (dexamethasone suppression test, late-night salivary cortisol and/or urinary 
free cortisol). 
Figure 2: Plasma glucose levels in oral glucose tolerance test (OGTT) of patients with 
primary aldosteronism (PA) depending on cortisol leve s after dexamethasone suppression 
test (DST), (autonomous cortisol secretion: cortisol levels >50nmol/l). Lines at 126mg/dl and 
200mg/dl indicating cut-offs for diagnosing diabetes mellitus by fasting plasma glucose and 
glucose after 120 minutes. Mild outliers (1.5-3xIQR) are displayed as circles and extreme 
outliers (> 3xIQR) displayed as stars. 
Figure 3: Frequencies of glucose metabolism alterations in patients with primary 
aldosteronism (PA) a) without (n=18) and b) with (n=58) autonomous cortisol secretion 
(ACS) in at least one test at baseline and at follow up-visit after one year. Dashed lines 
indicate changes within different subgroups, based on iagnosis at baseline visit. 
Table 1: Characteristics of primary aldosteronism (PA) patients with autonomous cortisol 
secretion (ACS) in at least one test and of PA patients without ACS (patients with normal test 
results regarding hypercortisolism). WHR = waist-to-hip ratio (analyzed separately for men 
and women due to different optimal values in males nd females); BMI = body mass index; 
BP= blood pressure; DST = dexamethasone suppression test; a= two missing values; b= three 
missing values; c= six missing values; d= ten missing values; e=12 missing values; f=30 
missing values. Data are displayed as mean ± SD for normally distributed continuous data, 
and as median; 25th and 75th percentile for continuous variables without normal distribution. 
Characteristics No ACS ACS P 
n (%) 36 (22.4) 125 (77.6) 0.000 
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Age (years) 49.3±11.3 51.9±11.1 0.218 
BMI (kg/m2) 27.0±4.7 27.3±5.1 (26.5; 23.5-29.0) 0.914 
Systolic BP (mmHg) 143±18.0 149±17.6 (147; 136-158) 0.092 
Diastolic BP (mmHg) 93.0±11.6 92.4±10.3 0.794 
Potassium (mmol/l) 3.6±0.4 (3.7; 3.4-3.9) 3.6±0.4 0.979 
WHR 




1.0±0.1d 0.036 0.670 
HbA1c (%) 5.2±0.4 (5.2; 4.9-5.5) 5.2±0.4 (5.2; 4.9-5.4) 0.919 
HDL-cholesterol (mg/dl) 63.4±17.1 60.0±15.8 (59.0; 46.0-71.0) 0.329 
LDL-cholesterol (mg/dl) 115±29.8 119±34.1 0.533 
Triglycerides (mg/dl) 98.8±44.8 (91.0; 61.3-137) 95.0±45.3 (88.0; 62.5-115) 0.633 
Total cholesterol (mg/dl) 194±33.0 194±34.9 0.983 
Statin therapy n (%) 4 (11.1) 11 (8.8) 0.674 
basal cortisol (µg/dl) 11.1±4.9 (10.2; 7.7-12.9) 13.5±5.3a (13.0; 10.0-16.5) 0.004 
basal ACTH (pg/ml) 19.0±20.0e (13.0; 7.0-23.5) 19.0±17.5f (15.0; 8.5-23.0) 0.776 
Cortisol after 1mg DST(nmol/l) 33.1±9.0 55.0±49.2 (41.4; 30.3-57.9) 0.001 
late night salivary cortisol (ng/ml) 0.8±0.3 1.8±1.3 (1.5; 0.9-2.3) 0.000 
Urinary free cortisol (µg/24h) 85.9±37.3 208±342 (171; 103-258) 0.000 
Hypo-/Normokalaemic PA (%) 61.1/38.9 64.0/36.0 0.751 
Table 2: Characteristics of primary aldosteronism (PA) patients without autonomous cortisol 
secretion (ACS) and matched controls from the KORA cohort. WHR = waist-to-hip ratio; 
BMI = body mass index; BP= blood pressure; OGTT = oral glucose tolerance test; m = 
matching variables; a= 4 missing values; b= 2 missing values. Data are displayed as mean ± 
SD for normally distributed continuous data, and as median; 25th and 75th percentile for 
continuous variables without normal distribution. 
Characteristics PA without ACS (n=35) KORA (n=105) P 
male n (%) 12 (34.3) 36 (34.3) m 
Age (years) 50.0±10.7 50.2±10.8 (49.0; 43.0-57.0) m 
BMI (kg/m2) 27.0±4.8 26.7±5.5 (26.2; 21.8-29.6) m 
Systolic BP (mmHg) 143±18.2 118±18.3 0.000 
Diastolic BP (mmHg) 92.9±11.7 75.5±10.2 0.000 
WHR 0.9±0.1
a
 0.8±0.1 (0.8; 0.8-0.9) 0.011 
Potassium (mmol/l) 3.6±0.4 (3.7; 3.4-3.9) 4.2±0.3 0.000 
HbA1c (%) 5.2±0.4 (5.2; 4.9-5.5) 5.4±0.8 (5.3; 5.1-.5) 0.054 
Fasting plasma glucose (mg/dl) 89.1±10.5 (87.0; 80.0-95.0) 94.9±27.5 (90.0; 85.5-97.0) 0.122 
2h OGTT glucose (mg/dl) 109±31.0 110±41.0 (100; 84.0-126) 
b
 0.885 
HOMA-IR 2.0±2.1 (1.2;0.9-2.3) 1.2±1.6 (0.8; 0.5-1.3) 0.051 
HOMA-β (%) 137±185  (92.5; 57.3- 133) 118±55.6  (106; 73.7-150) 0.378 
Diabetes mellitus n (%)  0 (0) 5 (4.8) 0.432 
Prediabetes n (%) 10 (28.6) 24 (22.9) 0.532 
Table 3: Characteristics of primary aldosteronism (PA) patients with pathological response in 
dexamethasone suppression test (pathDST) and matched controls from the KORA cohort. 
WHR = waist-to-hip ratio; BMI = body mass index; BP= blood pressure; OGTT = oral 
glucose tolerance test; m = matching variables; a= 2 missing values; b= 4 missing values; 
Data are displayed as mean ± SD for normally distribu ed continuous data, and as median; 
25th and 75th percentile for continuous variables without normal distribution.  
Characteristics PA with pathDST (n=34) KORA (n=102) P 
male n (%) 17 (50.0) 51 (50.0) m 
Age (years) 54.9±10.6 55.0±10.8 (57.0; 46.0-64.3) m 
BMI (kg/m2) 26.0±4.6 (25.2; 23.0-27.7) 26.0±4.5 (35.0; 22.7-28.5) m 
Systolic BP (mmHg) 151±21.1 (151; 140.5-161) 123±15-5 0.000 
Diastolic BP (mmHg) 94.1±12.4 75.6±9.2 0.000 
WHR  1.0±0.4 (0.9; 0.8-1.0)
a
 0.9±0.1 0.000 
Potassium (mmol/l) 3.5±0.4 4.2±0.3 0.000 
HbA1c (%) 5.3±0.5 5.5±0.4 (5.5; 5.2- 5.6) 0.013 
Fasting plasma glucose (mg/dl) 95.0±16.5 (92.0; 86.8-99.0) 96.7±16.6 (93.0; 87.0-103) 0.579 
2h OGTT glucose (mg/dl) 139±51.0 (127; 101-177) 107±33.3 (99-5; 86.0-120)
 b
 0.001 
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HOMA-β (%) 88.5±56.2  (71.4; 44.8-122) 108±53.8  (102.3; 72.2-130)b 0.056 
Diabetes mellitus n (%)  7 (20.6) 6 (5.9) 0.022 
Prediabetes n (%) 8 (23.5) 42 (41.2) 0.060 
Table 4: Characteristics of 76 patients with primary aldosteronism (PA) patients at baseline 
and at one-year follow-up. Number of hypertensives at follow-up does not include 
mineralocorticoid receptor antagonists (MRA). ADX = adrenalectomy; (no)ACS = no 
autonomous cortisol co-secretion in at least one test for hypercortisolism; BP = blood 
pressure; PAC = plasma aldosterone concentration; PRC = plasma renin concentration; ARR 
= aldosterone renin ratio; WHR = waist-to-hip ratio; BMI = body mass index; BP= blood 
pressure; a= one missing value; b= 5 missing values; c= 2 missing values; d= 4 missing 
values; Data are displayed as mean ± SD for normally distributed continuous data, and as 
median; 25th and 75th percentile for continuous variables without normal distribution. 
Variables 
ADX (n=25) MRA (n=48) Others (n=3) 
Baseline Follow-up P Baseline Follow-up P Baseline Follow-up 
noACS/ACS n (%) 3/22 (12/88) - 15/33 (31.2/68.8) - 2/1 (66.7/33.3) 
(unilateral/bilateral/unknown) (25/0/0)  (9/35/4)  (2/0/1) 
male n (%) 11 (44.0) - 25 (52.1) - 2 (66.7) 











0.000 148±21.0 131±12.1 
Diastolic BP (mmHg) 89.8±8.0 89.2±9.4 0.799 92.1±11.1 87.4±9.5 0.001 100±12.0 90.3±6.6 








































0.076 103±79.8 136±115 





























1.0±0.1b 0.126 0.9±0.1c 0.9±0.1d 0.875 1.5±1.0 0.8±0.1a 
HbA1c (%) 5.4±0.4 5.6±0.4 0.002 5.2±0.4 5.4±0.4a 0.006 5.0±0.4 5.2±0.3 




0.031 60.7±11.9 58.0±20.5 









0.000 88.0±9.1 130±102 


















































































































































































THE JOURNAL OF CLINICAL 
ENDOCRINOLOGY & METABOLISM
JCEM
















THE JOURNAL OF CLINICAL 
ENDOCRINOLOGY & METABOLISM
JCEM
















THE JOURNAL OF CLINICAL 
ENDOCRINOLOGY & METABOLISM
JCEM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2019-00299/5374695 by University of Zurich user on 21 March 2019
